MeiraGTx (MGTX) Competitors $7.09 +0.19 (+2.75%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGTX vs. GLPG, IDYA, ARQT, TVTX, AGIO, HRMY, EWTX, IRON, INDV, and KNSAShould you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Galapagos (GLPG), IDEAYA Biosciences (IDYA), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), Edgewise Therapeutics (EWTX), Disc Medicine (IRON), Indivior (INDV), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical products" industry. MeiraGTx vs. Galapagos IDEAYA Biosciences Arcutis Biotherapeutics Travere Therapeutics Agios Pharmaceuticals Harmony Biosciences Edgewise Therapeutics Disc Medicine Indivior Kiniksa Pharmaceuticals MeiraGTx (NASDAQ:MGTX) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership. Do institutionals & insiders believe in MGTX or GLPG? 67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 8.4% of MeiraGTx shares are owned by company insiders. Comparatively, 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate MGTX or GLPG? MeiraGTx currently has a consensus target price of $24.50, suggesting a potential upside of 245.56%. Galapagos has a consensus target price of $25.33, suggesting a potential downside of 5.89%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Galapagos 4 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is MGTX or GLPG more profitable? Galapagos has a net margin of 0.00% compared to MeiraGTx's net margin of -633.05%. Galapagos' return on equity of 0.00% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets MeiraGTx-633.05% -146.38% -53.05% Galapagos N/A N/A N/A Does the media favor MGTX or GLPG? In the previous week, Galapagos had 5 more articles in the media than MeiraGTx. MarketBeat recorded 13 mentions for Galapagos and 8 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.97 beat Galapagos' score of 0.64 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galapagos 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, MGTX or GLPG? Galapagos has higher revenue and earnings than MeiraGTx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMeiraGTx$33.28M16.80-$84.03M-$2.13-3.33Galapagos$288.19M6.16$80.16MN/AN/A Does the MarketBeat Community believe in MGTX or GLPG? Galapagos received 273 more outperform votes than MeiraGTx when rated by MarketBeat users. However, 71.75% of users gave MeiraGTx an outperform vote while only 63.75% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformMeiraGTxOutperform Votes19371.75% Underperform Votes7628.25% GalapagosOutperform Votes46663.75% Underperform Votes26536.25% Which has more volatility and risk, MGTX or GLPG? MeiraGTx has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. SummaryMeiraGTx beats Galapagos on 9 of the 16 factors compared between the two stocks. Get MeiraGTx News Delivered to You Automatically Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGTX vs. The Competition Export to ExcelMetricMeiraGTxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$559.08M$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-5.8630.4222.5718.48Price / Sales16.80498.92395.64103.60Price / CashN/A168.6838.1834.62Price / Book3.273.206.774.25Net Income-$84.03M-$72.35M$3.22B$248.23M7 Day Performance8.24%1.46%1.46%0.89%1 Month Performance15.10%8.79%3.98%3.53%1 Year Performance42.08%-22.36%16.14%5.09% MeiraGTx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGTXMeiraGTx4.5461 of 5 stars$7.09+2.8%$24.50+245.6%+45.3%$559.08M$33.28M-5.86300Upcoming EarningsShort Interest ↑Positive NewsGLPGGalapagos0.6174 of 5 stars$26.87+0.0%$25.33-5.7%-5.4%$1.77B$288.19M0.001,310Options VolumeHigh Trading VolumeIDYAIDEAYA Biosciences3.7112 of 5 stars$19.75+3.9%$53.58+171.3%-50.5%$1.73B$7M-5.9880Upcoming EarningsPositive NewsHigh Trading VolumeARQTArcutis Biotherapeutics2.7588 of 5 stars$14.53-0.5%$18.80+29.4%+79.2%$1.72B$196.54M-8.12150Upcoming EarningsPositive NewsGap DownTVTXTravere Therapeutics2.8971 of 5 stars$19.36+5.6%$32.08+65.7%+276.3%$1.72B$233.18M-4.72460News CoveragePositive NewsAGIOAgios Pharmaceuticals4.2318 of 5 stars$29.62+0.6%$56.57+91.0%-8.6%$1.70B$36.50M2.61390Analyst RevisionNews CoverageHRMYHarmony Biosciences4.8237 of 5 stars$29.36-0.8%$52.44+78.6%-4.7%$1.68B$714.73M13.91200Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsEWTXEdgewise Therapeutics3.2304 of 5 stars$15.68+5.7%$40.13+155.9%-8.6%$1.64BN/A-10.4560Upcoming EarningsAnalyst ForecastShort Interest ↑IRONDisc Medicine2.3683 of 5 stars$46.16+1.6%$93.80+103.2%+77.5%$1.60BN/A-11.6030Upcoming EarningsNews CoveragePositive NewsINDVIndivior3.3529 of 5 stars$11.57+0.1%$15.00+29.6%-34.5%$1.60B$1.17B-33.061,164Earnings ReportShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals2.4936 of 5 stars$21.47+0.5%$37.17+73.1%+44.1%$1.56B$423.24M-153.35220Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies GLPG Competitors IDYA Competitors ARQT Competitors TVTX Competitors AGIO Competitors HRMY Competitors EWTX Competitors IRON Competitors INDV Competitors KNSA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.